Onkológia 3/2023

Sacituzumab govitekan – drug profile

Sacituzumab govitecan is a new biopharmaceutical drug from the ADC class of drugs – antibody-drug conjugates, where monoclonal antibody is directed against Trop-2 antigen. Trop-2 is found on the surface of several human epithelial cancers. Drug linked to antibody is govitecan (SN-38), a well-known active metabolite of irinotecan and topoisomerase I inhibitor. Sacituzumab has demonstrated antitumor activity in TNBC (triple-negative breast cancer) (EMA and FDA registration), as well as in advanced, hormone receptor positive, HER2- negative breast cancer (FDA registration) and advanced bladder cancer (FDA registration). In the EMA approval for TNBC, results of the ASCENT study were positive based on doubling median overall survival from 6,7 months to 12,1 months (HR 0,48, p<0.001). These results lead to ESMO MCBS of 4. The most common toxicity was hematological and gastrointestinal (diarrhea). The research of this compound is continuing in various diagnoses such as lung cancer, urothelial cancer and other solid tumors.

Keywords: sacituzumab govitecan, breast cancer, bladder cancer, TNBC, ASCENT, SN-38, ADC